肿瘤坏死因子-α与哮喘及其拮抗剂治疗研究进展  

Progress of TNF-α and TNF-α blockade treatment in asthma

作　　者：李忠强(综述)[1] 王亚亭(审校)[1] 

机构地区：[1]安徽医科大学第一附属医院儿科,合肥230032

出　　处：《国际儿科学杂志》2010年第6期594-596,600,共4页International Journal of Pediatrics

摘　　要：支气管哮喘是呼吸道慢性疾病,发病机制复杂,是由多种炎症细胞及细胞因子参与的气道变态反应性疾病.肿瘤坏死因子-α（TNF-α）作为重要的炎性介质,参与哮喘的发病过程.哮喘时呼吸道上皮细胞、血管内皮细胞释放TNF-α,TNF-α可导致气道高反应和局部炎症,且与气道重建密切相关.研究表明抗TNF药物对哮喘患者气道重塑和重症哮喘有一定治疗作用,能下调血液及呼吸道中TNF-α水平,减低气道炎症反应,为治疗哮喘提供新的思路和方法.Asthma is a chronic inflammatory disease of the airways, pathogenesis is complex, variety of inflammatory cells and cytokines involved in the airway allergic diseases. Tumor necrosis factor-alpha（TNF-α）plays a role in the pathogenesis of asthma as an integral part of inflammatory mediators. Suffering from asthma,respiratory epithelial cells, vascular endothelial cells may release TNF-α which may cause airway hyperreactivity and the partial inflammation, and play a role in airway remodeling. The studies show that anti-TNF-α therapy has certain therapeutic action to airway remodeling in asthma patient and severe asthma, it can decline the level of TNF-α in the blood and the respiratory, reduce airway inflammation, provide new ideas and methods for the treatment of asthma.

关 键 词：哮喘 肿瘤坏死因子-Α 依那西普 

分 类 号：R587.1[医药卫生—内分泌]